{"id":53018,"date":"2023-01-18T09:02:53","date_gmt":"2023-01-18T08:02:53","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/longevity-biotech-gero-entered-a-research-collaboration-with-pfizer-to-discover-potential-targets-for-fibrotic-diseases\/"},"modified":"2023-01-18T09:02:53","modified_gmt":"2023-01-18T08:02:53","slug":"longevity-biotech-gero-entered-a-research-collaboration-with-pfizer-to-discover-potential-targets-for-fibrotic-diseases","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/longevity-biotech-gero-entered-a-research-collaboration-with-pfizer-to-discover-potential-targets-for-fibrotic-diseases\/","title":{"rendered":"Longevity Biotech Gero Entered a Research Collaboration With Pfizer to Discover Potential Targets for Fibrotic Diseases"},"content":{"rendered":"
\n

SAN FRANCISCO–(BUSINESS WIRE)–Gero<\/a> today announced that it has entered into a research collaboration with Pfizer<\/a> to apply Gero\u2019s machine learning technology platform to discover potential therapeutic targets for fibrotic diseases using large-scale human-based data.\n<\/p>\n

<\/a><\/p>\n

\nAs part of this research collaboration, the companies will leverage Pfizer’s expertise and Gero\u2019s technology platform with the aim to identify genes and pathways linked to fibrotic diseases. Pfizer may advance the potential therapeutic targets and would be responsible for further preclinical and clinical development.\n<\/p>\n

\n\u201cHuman data-driven drug discovery avoids the \u201cpreclinical trap\u201d and has the potential to identify clinically relevant targets against human (not rodent) diseases. However, genetics-based target identification against age-related diseases is hindered by the irreversible component of human aging,\u201d<\/i> said Peter Fedichev, CEO of Gero. \u201cOur technology platform allows us to separate irreversible effects of aging from reversible disease phenotypes to potentially identify the most actionable therapeutic targets.\u201d<\/i>\n<\/p>\n

\nGero will receive an upfront payment and is eligible to receive discovery milestone payments if the project progresses.\n<\/p>\n

\n\u201cWe are excited to work with Pfizer, one of the world\u2019s leading biopharmaceutical companies, to potentially identify targets against fibrotic diseases, which have a large unmet need,\u201d <\/i>said Alex Kadet, CBO of Gero. \u201cWe believe that combining our platform technology with Pfizer\u2019s extensive disease expertise has the potential to identify high-value targets in this disease area.\u201d<\/i>\n<\/p>\n

\nAbout Gero\n<\/p>\n

\nGero is a preclinical-stage physics-enabled biotechnology company creating therapeutics against chronic diseases with a mission to slow down human aging itself.\n<\/p>\n

\nGero applies machine learning algorithms originating from the physics of complex systems to build clinically relevant disease progression models (phenotypes) in real-world human data and identify clusters of diseases with shared biology. Then the AI-enhanced genetic study on the phenotypes in conjunction with Whole-Exome sequencing data reveals novel therapeutic targets potentially applicable to several indications simultaneously.\n<\/p>\n

\nGero\u2019s research has been published in Nature Communications (1<\/a>, 2<\/a>, 3<\/a>) and Science<\/a> journals and is covered by Scientific American<\/a>.\n<\/p>\n

Contacts<\/b> <\/p>\n

\nFor all media<\/i> inquiries<\/i>
Daria Dinze
\n
dinze@icantell.agency<\/a><\/p>\n

Antonia Monzani
\n
antonia@icantell.agency<\/a>\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

SAN FRANCISCO–(BUSINESS WIRE)–Gero today announced that it has entered into a research collaboration with Pfizer to apply Gero\u2019s machine learning technology platform to discover potential therapeutic targets for fibrotic diseases using large-scale human-based data. As part of this research collaboration, the companies will leverage Pfizer’s expertise and Gero\u2019s technology platform with the aim to identify … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-53018","6":"format-standard","7":"category-industry"},"yoast_head":"\nLongevity Biotech Gero Entered a Research Collaboration With Pfizer to Discover Potential Targets for Fibrotic Diseases - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/longevity-biotech-gero-entered-a-research-collaboration-with-pfizer-to-discover-potential-targets-for-fibrotic-diseases\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Longevity Biotech Gero Entered a Research Collaboration With Pfizer to Discover Potential Targets for Fibrotic Diseases - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"SAN FRANCISCO–(BUSINESS WIRE)–Gero today announced that it has entered into a research collaboration with Pfizer to apply Gero\u2019s machine learning technology platform to discover potential therapeutic targets for fibrotic diseases using large-scale human-based data. As part of this research collaboration, the companies will leverage Pfizer’s expertise and Gero\u2019s technology platform with the aim to identify ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/longevity-biotech-gero-entered-a-research-collaboration-with-pfizer-to-discover-potential-targets-for-fibrotic-diseases\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2023-01-18T08:02:53+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20230117005897\/en\/1687913\/21\/OB19mU2.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/longevity-biotech-gero-entered-a-research-collaboration-with-pfizer-to-discover-potential-targets-for-fibrotic-diseases\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/longevity-biotech-gero-entered-a-research-collaboration-with-pfizer-to-discover-potential-targets-for-fibrotic-diseases\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Longevity Biotech Gero Entered a Research Collaboration With Pfizer to Discover Potential Targets for Fibrotic Diseases\",\"datePublished\":\"2023-01-18T08:02:53+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/longevity-biotech-gero-entered-a-research-collaboration-with-pfizer-to-discover-potential-targets-for-fibrotic-diseases\\\/\"},\"wordCount\":355,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/longevity-biotech-gero-entered-a-research-collaboration-with-pfizer-to-discover-potential-targets-for-fibrotic-diseases\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230117005897\\\/en\\\/1687913\\\/21\\\/OB19mU2.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/longevity-biotech-gero-entered-a-research-collaboration-with-pfizer-to-discover-potential-targets-for-fibrotic-diseases\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/longevity-biotech-gero-entered-a-research-collaboration-with-pfizer-to-discover-potential-targets-for-fibrotic-diseases\\\/\",\"name\":\"Longevity Biotech Gero Entered a Research Collaboration With Pfizer to Discover Potential Targets for Fibrotic Diseases - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/longevity-biotech-gero-entered-a-research-collaboration-with-pfizer-to-discover-potential-targets-for-fibrotic-diseases\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/longevity-biotech-gero-entered-a-research-collaboration-with-pfizer-to-discover-potential-targets-for-fibrotic-diseases\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230117005897\\\/en\\\/1687913\\\/21\\\/OB19mU2.jpg\",\"datePublished\":\"2023-01-18T08:02:53+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/longevity-biotech-gero-entered-a-research-collaboration-with-pfizer-to-discover-potential-targets-for-fibrotic-diseases\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/longevity-biotech-gero-entered-a-research-collaboration-with-pfizer-to-discover-potential-targets-for-fibrotic-diseases\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/longevity-biotech-gero-entered-a-research-collaboration-with-pfizer-to-discover-potential-targets-for-fibrotic-diseases\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230117005897\\\/en\\\/1687913\\\/21\\\/OB19mU2.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230117005897\\\/en\\\/1687913\\\/21\\\/OB19mU2.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/longevity-biotech-gero-entered-a-research-collaboration-with-pfizer-to-discover-potential-targets-for-fibrotic-diseases\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Longevity Biotech Gero Entered a Research Collaboration With Pfizer to Discover Potential Targets for Fibrotic Diseases\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Longevity Biotech Gero Entered a Research Collaboration With Pfizer to Discover Potential Targets for Fibrotic Diseases - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/longevity-biotech-gero-entered-a-research-collaboration-with-pfizer-to-discover-potential-targets-for-fibrotic-diseases\/","og_locale":"en_US","og_type":"article","og_title":"Longevity Biotech Gero Entered a Research Collaboration With Pfizer to Discover Potential Targets for Fibrotic Diseases - Pharma Trend","og_description":"SAN FRANCISCO–(BUSINESS WIRE)–Gero today announced that it has entered into a research collaboration with Pfizer to apply Gero\u2019s machine learning technology platform to discover potential therapeutic targets for fibrotic diseases using large-scale human-based data. As part of this research collaboration, the companies will leverage Pfizer’s expertise and Gero\u2019s technology platform with the aim to identify ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/longevity-biotech-gero-entered-a-research-collaboration-with-pfizer-to-discover-potential-targets-for-fibrotic-diseases\/","og_site_name":"Pharma Trend","article_published_time":"2023-01-18T08:02:53+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20230117005897\/en\/1687913\/21\/OB19mU2.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/longevity-biotech-gero-entered-a-research-collaboration-with-pfizer-to-discover-potential-targets-for-fibrotic-diseases\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/longevity-biotech-gero-entered-a-research-collaboration-with-pfizer-to-discover-potential-targets-for-fibrotic-diseases\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Longevity Biotech Gero Entered a Research Collaboration With Pfizer to Discover Potential Targets for Fibrotic Diseases","datePublished":"2023-01-18T08:02:53+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/longevity-biotech-gero-entered-a-research-collaboration-with-pfizer-to-discover-potential-targets-for-fibrotic-diseases\/"},"wordCount":355,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/longevity-biotech-gero-entered-a-research-collaboration-with-pfizer-to-discover-potential-targets-for-fibrotic-diseases\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20230117005897\/en\/1687913\/21\/OB19mU2.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/longevity-biotech-gero-entered-a-research-collaboration-with-pfizer-to-discover-potential-targets-for-fibrotic-diseases\/","url":"https:\/\/pharma-trend.com\/en\/longevity-biotech-gero-entered-a-research-collaboration-with-pfizer-to-discover-potential-targets-for-fibrotic-diseases\/","name":"Longevity Biotech Gero Entered a Research Collaboration With Pfizer to Discover Potential Targets for Fibrotic Diseases - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/longevity-biotech-gero-entered-a-research-collaboration-with-pfizer-to-discover-potential-targets-for-fibrotic-diseases\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/longevity-biotech-gero-entered-a-research-collaboration-with-pfizer-to-discover-potential-targets-for-fibrotic-diseases\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20230117005897\/en\/1687913\/21\/OB19mU2.jpg","datePublished":"2023-01-18T08:02:53+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/longevity-biotech-gero-entered-a-research-collaboration-with-pfizer-to-discover-potential-targets-for-fibrotic-diseases\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/longevity-biotech-gero-entered-a-research-collaboration-with-pfizer-to-discover-potential-targets-for-fibrotic-diseases\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/longevity-biotech-gero-entered-a-research-collaboration-with-pfizer-to-discover-potential-targets-for-fibrotic-diseases\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20230117005897\/en\/1687913\/21\/OB19mU2.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20230117005897\/en\/1687913\/21\/OB19mU2.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/longevity-biotech-gero-entered-a-research-collaboration-with-pfizer-to-discover-potential-targets-for-fibrotic-diseases\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Longevity Biotech Gero Entered a Research Collaboration With Pfizer to Discover Potential Targets for Fibrotic Diseases"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/53018","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=53018"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/53018\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=53018"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=53018"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=53018"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}